US Insulin Pump Market to Reach USD 4 Bn by 2022, Forecasts DPI Research in Its New Comprehensive Report Available at MarketPublishers.com
20 Mar 2017 • by Natalie Aster
LONDON – The insulin pump marketplace in the USA is poised to gain momentum in the offing and be worth USD 4 billion by 2022-end.
The growth in the market is stimulated by certain factors like the surging awareness about diabetes, number of people with diabetes, enhanced control of glucose levels and resilient, lifestyle-compatible treatment modalities along with technology advances in insulin infusion pump devices. Meantime, high prices of the insulin pumps are impeding the sector’s growth.
Insulet Corporation, Roche, Tandem Diabetes Care, Medtronic, and Animas Corporation are the companies dominating the marketplace.
New comprehensive report “United States Insulin Pump Market” drawn up by DPI Research provides an extensive, granular assessment of the insulin pump market performance on a country level.
The report offers a detailed evaluation of the type 1, type 2 and recently diagnosed type 1 diabetes as well as examines the total diabetes population. It offers deep, unprejudiced insights into the users of insulin pumps, specifically focusing on the insulin pump users diagnosed with type 1 and type 2 diabetes. The report provides the outlook for the market value. It offers an all-round view of reimbursement and regulation systems. The report also offers an evaluation of clinical by phase, firm and country. It gives a granular analysis of the major trends relating to deals in the marketplace. The report also canvasses the growth drivers and limiters of the country’s insulin pump marketplace. Additionally, the study profiles the dominant players, evaluating them on different parameters such as business overview, product forecasts and sales analysis of the domestic insulin pump and diabetes marketplace.
More new studies by the publisher can be found at DPI Research page.